Physical Exercise Modulates L-DOPA-Regulated Molecular Pathways in the MPTP Mouse Model of Parkinson’s Disease

Cornelius J. H. M. Klemann1 · Helena Xicoy1,2 · Geert Poelmans1,3 · Bas R. Bloem4 · Gerard J. M. Martens1 · Jasper E. Visser1,4,5

Received: 28 April 2017 / Accepted: 15 September 2017 / Published online: 10 October 2017
© The Author(s) 2017. This article is an open access publication

Abstract Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc), resulting in motor and non-motor dysfunction. Physical exercise improves these symptoms in PD patients. To explore the molecular mechanisms underlying the beneficial effects of physical exercise, we exposed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine (MPTP)-treated mice to a four-week physical exercise regimen, and subsequently explored their motor performance and the transcriptome of multiple PD-linked brain areas. MPTP reduced the number of DA neurons in the SNpc, whereas physical exercise improved beam walking, rotarod performance, and motor behavior in the open field. Further, enrichment analyses of the RNA-sequencing data revealed that in the MPTP-treated mice physical exercise predominantly modulated signaling cascades that are regulated by the top upstream regulators L-DOPA, RICTOR, CREB1, or bicuculline/dalfampridine, associated with movement disorders, mitochondrial dysfunction, and epilepsy-related processes. To elucidate the molecular pathways underlying these cascades, we integrated the proteins encoded by the exercise-induced differentially expressed mRNAs for each of the upstream regulators into a molecular landscape, for multiple key brain areas. Most notable was the opposite effect of physical exercise compared to previously reported effects of L-DOPA on the expression of mRNAs in the SN and the ventromedial striatum that are involved in—among other processes—circadian rhythm and signaling involving DA, neuropeptides, and endocannabinoids. Altogether, our findings suggest that physical exercise can improve motor function in PD and may, at the same time, counteract L-DOPA-mediated molecular mechanisms. Further, we hypothesize that physical exercise has the potential to improve non-motor symptoms of PD, some of which may be the result of (chronic) L-DOPA use.

Keywords Parkinson’s disease · Physical exercise · MPTP · L-DOPA · (Non-)motor function · Molecular landscape

Introduction

Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). The clinical phenotype encompasses motor symptoms—including bradykinesia, rigidity, tremor, gait dysfunction, and postural instability—and non-motor symptoms such as sleeping disturbances, pain, or cognitive deficits that affect executive functions, attention, mood, and working memory [1–3]. Levodopa (L-DOPA), a precursor of DA, has been used since the 1960s to treat PD motor symptoms and is still considered the gold standard of therapy [4, 5]. In recent years, physical exercise—including intervention strategies
such as aerobic exercise (e.g., treadmill exercise, cycling, or dancing) or strength training (e.g., using a modified fitness counts program or progressive resistance exercising)—has been reported to improve DA signaling [6, 7] and motor dysfunction [8–11], including bradykinesia [12, 13], rigidity [14], and tremor [12]. Physical exercise has also been reported to improve less dopamine-dependent symptoms involving postural control such as turning performance [6] and instability [15], as well as cognitive function [2, 16, 17] in PD patients. Although these beneficial clinical effects of exercise on PD symptoms are evident, the underlying molecular mechanisms are not well understood. A better understanding of these processes may ultimately lead to a more efficient treatment of these symptoms, through directly targeting the underlying pathways.

Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice results in the loss of nigrostriatal DA neurons, and is widely used to study the pathophysiological mechanisms underlying DA neuron degeneration in PD [18]. Moreover, similar to human PD, physical exercise improves motor behavior and reduces cognitive impairment in MPTP-treated mice [19–23]. To our knowledge, in this study, we elucidate for the first time the molecular pathways underlying the beneficial effects of exercise in PD, using the MPTP mouse model of PD.

Methods

Animals

Six-month-old male C57BL/6J mice were housed, five to a cage, with ad libitum access to food and water and at a constant 12/12 h light/dark cycle (lights on between 07:00 and 19:00 h). Room temperature was controlled at 21 °C and rooms were homogenously lighted by 60 LUX with controlled humidity. Following arrival, the mice were acclimatized to their new housing for 1 week, after which they were randomly assigned to one of four treatment groups: (1) saline-treated; (2) saline-treated with physical exercise; (3) MPTP-treated; and (4) MPTP-treated with physical exercise. MPTP-HCl (Sigma-Aldrich) dissolved in saline was administered via four intraperitoneal injections at 2 h intervals, amounting to a total administered dose of 70 mg/kg (free-base), which in a dose-response pilot experiment was found as the highest tolerable dose, with a survival rate of 75%. The intended concentration of 80 mg/kg, based on similar previous experiments [7, 24, 25], resulted in a higher toxicity and death rate that could not be justified. The control mice underwent the same protocol using saline injections. Mice were allowed to recover from the injections for 2 weeks. All saline-treated mice survived the protocol, n = 14 for group (1) and n = 14 for group (2), whereas, due to MPTP treatment, group (3) and group (4) eventually consisted of n = 10 and n = 13 mice, respectively.

Physical Exercise

A forced chronic and aerobic physical exercise regimen was initiated 3 weeks following MPTP or saline treatment and was performed daily. Mice ran 30 min twice a day during a training period of 28 consecutive days in individual, horizontal lanes on a five-lane treadmill (Panlab Harvard Apparatus) at a speed of 20 cm/s (as used before in comparable experimental setups [7, 24, 26, 27]). Automated short air puffs were used to stimulate the mice to keep running when drifting too far to the back of the lane. All mice were able to perform the physical exercise without any noticeable problems. Mice assigned to the groups without physical exercise were placed in their housing cage in the same experimental room, adjacent to the treadmill.

Behavioral Testing

Behavioral testing commenced 1 week before the physical exercise regimen started (week 0), and was repeated each week (similar to comparable experiments by others [7, 28–30]) during the exercise regimen (weeks 1–4): beam walk on the first, rotarod on the third, and open field on the fifth day of each week, in each case performed between 08:00 and 13:00 h. Prior to all behavioral tests, the animals of all four treatment groups were habituated to the experimental room for 1 h. Mice from different treatment groups were tested concurrently on the rotarod and in the open field.

Open Field

The mice were placed in a white plexiglass box (50×50×40cm) and video recorded from above for 30 min using EthoVision XT 7.0 software (Noldus Information Technology B.V., Wageningen, The Netherlands). Afterwards, the parameters “total walking distance”, “total movement time”, “mean velocity”, and “mean angular velocity” were calculated by the software, as described previously [31].

Rotarod

Mice were placed on the rotarod apparatus (IITC Inc., Woodland Hills, CA, USA) with a rod diameter of 32 mm and an increasing speed of 4 to 38 rpm in 300 s. Five mice were tested simultaneously on the rotarod and their latency to fall was measured (similar to [7, 30, 32]). On each testing day, each mouse performed one pre-trial and three trials, each with a maximum duration of 300 s and with a minimum of 1 h of rest between the trials. The pre-trial enabled the mice to habituate (again) to the rotarod and was not included in the results.
For each testing day, the latency times of the three trials were averaged per mouse.

**Beam Walk**

We assessed the motor coordination and balance by measuring the ability of the mice to transverse a narrow beam [28, 33]. The mice were placed on a white plasticized iron rod (full length 80 cm, diameter 10 mm) suspended at 40 cm height and were trained to cross the beam to their home cage. Training of the mice occurred on the first day. During the training, the distance to cross was increased each time they successfully reached their cage, until they were able to reach their home cage over the full length of the beam. Each week, the mice were habituated again to the experimental setup by a pre-trial, which was followed by three trials in which the time was recorded how long it took for the mice to cross the full beam to reach their home cage; inter-trial interval was in all cases at least 1 h. For each testing day, the times of the three trials were averaged per mouse.

**Immunohistochemistry**

We performed immunohistochemistry to establish TH protein expression [24, 34] in the DL, VM, SNpc, and VTA. Twenty-four hours following their last exercise training, mice were sacrificed by cervical dislocation, and brains were dissected and fixed in 4% paraformaldehyde in PBS solution for 3 h and subsequently cryoprotected by immersion in 30% sucrose for 24 h. After cryosectioning, DAB staining was performed on 20-μm-thick coronal slices, placed on gelatinized glass slides. For this, the sections were washed with PBS (3×10min), non-specific sites blocked with blocking buffer (2.5% normal donkey serum, 2.5% normal goat serum, 1% BSA, 1% glycine, 0.1% lysine, and 0.4% Triton X-100 in PBS) for 30 min and incubated with rabbit anti-tyrosine hydroxylase (TH, 1:1000; Pel-Freez Biologicals #P40101-0; lot no. 19335) for 16 h at 4 °C. This was followed by a 1 h incubations with biotinylated goat-anti-rabbit (1:200; Jackson ImmunoResearch; 711-065-152; lot no.117858) and avidin-biotin-peroxidase complex (A and B 1:800; Vectastain Elite ABC kit, PK-6100 Standard), with PBS washing steps in between. To visualize antibody binding, the sections with SNpc and ventral tegmental areas (VTA) were incubated for 30 min, and those with dorsolateral striatum (DL) and ventromedial striatum (VM) areas were incubated for 20 min in a DAB/H2O2-solution potentiated by ammonium nickel sulfate. The sections were subsequently dehydrated and cover slipped. For each mouse, every sixth section throughout the DL, VM, SNpc, and VTA was included in the counting procedure, and for optimal comparison between groups, sections of different treatment groups were stained concurrently.

Images were captured by a Leica DM6000 B microscope. TH-positive (TH+) cells were counted in the sections of the SNpc (−2.54 to −3.88 mm to Bregma [35]) and VTA (−2.92 to −3.88 mm to Bregma [35]), using a 20× magnification. The number of TH+ cells in each section (both the left and right side) was counted by a blinded assessor and averaged over the total number of sections per animal. DA fiber density was estimated in the DL (1.18 to −0.10 mm to Bregma [35]) and VM (1.54 to 0.62 mm to Bregma [35]) by quantifying the optic density (OD) with FIJI [36], using a 5× magnification. In both areas, the OD per section was determined by averaging the OD of ten separate areas within the striatal matrix (i.e., in-between the striosomes). Subsequently, the OD was normalized by subtracting the OD of the corpus callosum (CC) or anterior commissure (AC) for the DL and VM respectively, in the same section, and all sections were averaged per animal.

**RNA Isolation and Sample Preparation**

Twenty-four hours following the last physical exercise training, brains of 8–10 mice per group—that were sacrificed by cervical dislocation—were dissected, immediately frozen on dry ice, and stored at −80 °C until further preparation. Specific brain areas, i.e., prefrontal cortex (PFC), DL, VM, VTA, SN, and pedunculopontine nucleus (PPN), were then cryopunched based on the stereotaxic atlas of the mouse brain [35] from 200-μm-thick coronal slices, using punch needles with a diameter of 0.5 and 0.75 mm (see Online Resource 1 for the estimated punching locations per area). All specimens were kept at −20 °C during processing. For RNA isolation, punched samples were homogenized with a TissueLyser (Retsch GmbH) in 800 μL TRIzol reagent and RNA isolation was performed according to the manufacturer’s instructions (Invitrogen). Total RNA concentration was determined with a Nanodrop™ ND-1000 spectrophotometer (Thermo Fisher Scientific Inc.), and RNA quality was visually assessed by 1% agarose gel electrophoresis. Genomic DNA was removed by treatment with DNase I in the presence of RNAsin (Thermo Fisher) in 5× FSB buffer and RNase-free water. Subsequently, total RNA samples were stored at −80 °C until further use. For each treatment group and brain area, RNA samples of six mice were pooled for RNAseq analysis.

**RNA Sequencing and Data Processing**

All RNA samples were subjected to RNA sequencing (RNAseq; HudsonAlpha Genomic Services Lab, Huntsville, AL) as performed before [37]. In short, total RNA concentration was estimated by Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA, USA) and RNA integrity by using the Agilent 2100 Bioanalyzer (Applied Biosystems, Carlsbad, CA, USA). RNAseq libraries were formed from
approximately 500 ng total RNA of each pooled sample, followed by poly(A) enrichment. RNAseq was performed using paired-end sequencing on Illumina HiSeqH2000 (Illumina, San Diego, CA, USA), at 50 base pairs, generating over 25 million paired reads per sample. Raw RNAseq FASTQ files were demultiplexed by bcl2fastq conversion software v1.8.3 (Illumina, Inc., San Diego, CA, USA) using default settings.

RNAseq data was analyzed using GeneSifter software (VizX Labs, Seattle, WA). RNAseq reads were mapped to the *Mus musculus* reference genome build 37.2, and for this, the reads were trimmed by 15 base pairs at the five-prime end. Subsequently, transcript abundance was calculated by estimating the reads per kilobase of exon per million mapped reads (RPKM), and normalization to the number of mapped reads was used for comparison of two mRNA sets. A t test was used for pairwise comparison and a likelihood ratio test to adjust for distribution probability.

**qPCR Validation**

The RNAseq results were validated by comparing expression levels of at least eight mRNAs/genes per area with their expression as established by qPCR. These genes were chosen randomly, although there was one requirement, namely that genes from all three comparisons of interest, i.e., the comparisons to assess the effect of MPTP (group 3 vs. group 1), physical exercise (group 2 vs. group 1), and physical exercise in the MPTP model of PD (group 4 vs. group 3), should be included. RNA from the same samples used for the RNAseq pools was reverse-transcribed to cDNA with random primers using the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Scientific, #K1632 lot no 00167909) according to the manufacturer’s protocol. Three-step qPCR (95 °C for 10 min, followed by 45 three-step cycles of 95 °C for 5 s, 65 °C for 10 s, and 72 °C for 20 s, and the generation of melting curves from 70 °C to 95 °C; Rotor-Gene 6000 Series, Corbett Life Science Pty. Ltd.) was performed using the 2× SensiFAST SYBR No-ROX mix (Bioline lot no SF582-313209) and primers designed with NCBI Primer-Blast (www.ncbi.nlm.nih.gov/tools/primerblast/) and synthesized at Sigma Life Sciences (The Netherlands) (For a complete overview of used primers, see Online Resource 10, Supp. Table 1). The housekeeping genes ACTB and YWHAZ were used as reference for normalization of gene expression. Based on the qPCR results, the minimum requirements to be included in the enrichment analysis—regarding fold change (FC) cut-off, maximum likelihood ratio value, and minimal RPKM value—were adjusted so that at least 90% of the expression changes could be validated by qPCR. As there was insufficient remaining RNA available to perform the complete qPCR validation for the PPN RNAseq data, the same cut-off values were used as for the other brain areas.

**Overlap of MPTP- and Exercise-Regulated Genes**

To determine the direct effect of exercise on MPTP-regulated genes, we looked at the overlap between the genes regulated by MPTP (group 3 vs. group 1) and the genes regulated by exercise in the MPTP model (group 4 vs. group 3). To quantify this overlap, we used the hypergeometric distribution test \[^{[38]}\]:

\[
p(x|n,M,N) = \binom{M}{x} \binom{N-M}{n-x} / \binom{N}{n}
\]

and determined the chance of observing exactly \(x\) overlapping genes from a total of \(n\) differentially expressed genes by exercise in the MPTP model, with a total of \(M\) genes that were differentially expressed by MPTP and a total of \(N\) genes detected with RNAseq. The number of unique genes detected with RNAseq in each brain area (\(N\)), consists of genes detected in both comparisons (group 3 vs. group 1 and group 4 vs. group 3), irrespective of their FC or expression \(p\) value. Of note, for all comparisons only protein-coding genes were considered.

**Enrichment Analysis and Building of Molecular Landscapes**

The Ingenuity pathway analysis software package (www.ingenuity.com) was used to identify enriched categories in the lists of differentially expressed protein-coding mRNAs in each of the brain areas \[^{[39]}\]. Again, we focused on the three main comparisons of interest (see above)—i.e., the comparisons that assess the effect of MPTP, physical exercise, and physical exercise in the MPTP model of PD—in the six brain areas. Ingenuity assigns genes or rather their corresponding mRNAs/proteins to functional (sub)-categories, i.e., “canonical pathways” and “biofunctions”, with the latter including “diseases and disorders” and “molecular and cellular functions”. In addition, Ingenuity generates a list of “upstream regulators”, i.e., proteins or compounds that regulate multiple proteins/mRNAs from the input list. When possible, the program also calculates a \(z\) score that is based on the expression changes of the input mRNAs and that is a measure for the directionality of the upstream regulator, canonical pathway, or biofunction. A \(z\) score \(< -2\) or \(> 2\) is considered significant. For all analyses, only functional categories and upstream regulators with
significant enrichment (i.e., Benjamini-Hochberg corrected $p < 0.05$) and containing at least two genes were taken into account.

Proteins/mRNAs regulated by the top upstream regulators were analyzed in more depth to identify their relation to physical exercise-induced processes in the MPTP model of PD (i.e., the comparison of group 4 with group 3). Guided by the results of the Ingenuity enrichment analyses, an extensive literature search was performed for the (putative) roles of all proteins encoded by the differentially expressed mRNAs as well as their functional interactions, using the UniProt Protein Knowledge Base (http://www.uniprot.org) and PubMed (http://www.ncbi.nlm.nih.gov/pubmed). Based on these findings and applying an approach similar to the one we used previously for genome-wide association and expression data [39–42], we then built molecular landscapes containing interacting proteins encoded by the mRNAs that are differentially expressed by physical exercise and are known to be regulated by the top regulators for each brain area. To complement these protein interaction cascades, we added a number of proteins that were not encoded by the differentially expressed mRNAs but that have been implicated in PD etiology through other lines of (genetic) evidence. In this respect, proteins encoded by familial PD candidate genes were included if they have at least one functional interaction with one or more other landscape proteins. Additional proteins were included when having at least two interactions with other landscape proteins. The molecular landscapes were drawn with Serif DrawPlus 4.0.

Statistics

Statistical comparisons of values between multiple treatment groups were carried out using a two-way ANOVA. For behavioral test data, with data at multiple time points, a linear mixed model was applied using SPSS (IBM, version 23), with “week”, “physical exercise”, and “MPTP” as fixed factors to calculate the main effects of the training period, physical exercise, and the interaction between physical exercise and MPTP. The main effect of MPTP in the behavioral tests was assessed using a pairwise comparison of saline-treated and MPTP-treated mice before the start of the exercise regimen. For pairwise comparison, an $F$ test was used to determine if the distributions of the compared two groups have the same variance. Based on the $F$ test, a Student’s $t$ test for equal or unequal variance was then used to evaluate the significance of the expression differences. For all comparisons, data are represented as mean with the standard error of the mean (SEM), and a $p$ value $< 0.05$ was considered statistically significant.

The $p$ values calculated with the hypergeometric distribution test were adjusted for multiple testing using the Bonferroni correction.

Results

In this study, we assessed the effects of physical exercise in the MPTP-treated mouse model of PD at the behavioral and molecular levels.

![Fig. 1 Effect of MPTP. Results of the behavioral tests in week 0 (set as the baseline (100%) for the effect of physical exercise, which is shown in Fig. 2). No effect of MPTP was shown for the beam walk (a), or rotarod (b) tests, but MPTP significantly affects the parameters in the open field (c–f). **$p < 0.01$; ***$p < 0.005$, mean + SEM, $n = 28$ for controls (saline-treated), and $n = 23$ for MPTP-treated mice.](image-url)
Physical Exercise Affects the Motor Function of MPTP-Treated Mice

At baseline, i.e., following recovery from MPTP treatment but before the exercise regimen started, MPTP-treated mice showed an increased total walking distance ($p < 0.01$), total movement time ($p < 0.005$), and mean velocity ($p < 0.005$), and a decreased mean angular velocity ($p < 0.005$) in the open field compared to saline-treated control mice. In contrast, their performance on rotarod and beam walk tests was not significantly different from controls (Fig. 1).

In Fig. 2, the effects of physical exercise during the course of the training period relative to baseline are shown for each of the four treatment groups. The beam walk task showed a clear training effect over time in all groups (main effect of “week” $p < 0.001$), and the test performance was improved by physical exercise in both the MPTP-treated and saline-treated mice, without significant differences between the groups (main effect of physical exercise $p < 0.05$) and no significant interaction between physical exercise and MPTP treatment (Fig. 2a). Rotarod performance was also significantly improved by physical exercise ($p < 0.01$), but no improvement over time or interaction with MPTP treatment was found (Fig. 2b). Of the tested parameters in the open field (total walking distance, total movement time, mean velocity, and mean angular velocity), the mean angular velocity was increased ($p < 0.001$), and the total movement time showed a decreasing trend ($p = 0.051$) for all treatment groups over time during the exercise regimen (i.e., main effect of “week”). There was no significant (main) effect of physical exercise on any of the four tested open field parameters, only a trend towards a higher “mean velocity” ($p = 0.082$). However, for all four open field parameters, significant

**Fig. 2** Effect of physical exercise and interaction with MPTP compared to the baseline (week 0); results of the behavioral tests in week 0–4. Measurements in week 1–4 were normalized to week 0 (100%). Dark-orange arrows indicate the main effect of physical exercise (a, b), and light orange arrows show the effect of the interaction between physical exercise and MPTP treatment (c–f) mean ± SEM $n = 14$ for both CNR and CR, $n = 10$ for MNR and $n = 13$ for MR. CNR, control not running; CR control running, MNR MPTP-treated but not running, MR MPTP-treated and running.
interactions between physical exercise and MPTP treatment were found \((p < 0.05)\). Physical exercise increased the walking distance and mean velocity of saline-treated mice, but not of MPTP-treated mice. Moreover, physical exercise increased the total movement time of saline-treated mice and decreased that of MPTP-treated mice. This opposite effect was also observed for mean angular velocity, i.e., a decrease by physical exercise in saline-treated mice and an increase in MPTP-treated mice (Fig. 2c–f).

**TH Depletion in the SNpc and Striatum Following MPTP Treatment**

The number of DA neurons in the SNpc and VTA of each treatment group, as well as an estimate of DA fiber density in striatal target areas (DL and VM, respectively) was determined by immunohistochemistry for TH—the rate-limiting enzyme in DA synthesis. These measures were primarily taken to confirm and estimate the degree of neuronal loss due to MPTP treatment, but they may also provide some insight into whether exercise could affect these structural changes. MPTP significantly reduced the number of TH+ cells in the SNpc \((p < 0.005)\), but not in the VTA. Pairwise comparison between the treatment groups revealed that the number of TH+ cells in the SNpc of MPTP-treated mice without and with physical exercise was reduced by 29 and 20%, respectively, compared to the saline-treated group without exercise (both \(p < 0.05\); Fig. 3). There was no significant effect of physical exercise on the number of TH+ cells in either the SNpc or the VTA, and no interaction between MPTP and physical exercise.

In Online Resource 2, the relative OD of TH+ fibers in the DL, the primary striatal target area of the SNpc, is shown. The OD of TH+ fibers was reduced by MPTP \((p < 0.05)\), without a main effect of physical exercise or an interaction between MPTP and physical exercise. Pairwise comparison showed that MPTP decreased the density of TH+ fibers in MPTP-treated mice without exercise by 33% \((p < 0.005)\) compared to saline-treated mice without physical exercise. There was a trend towards an increased TH+ OD by physical exercise in MPTP-treated mice, but this increase was not significant.

Online Resource 3 shows the OD of TH+ fibers in the VM, the primary striatal target area of the VTA. Although all treatment groups (physical exercise, MPTP, and MPTP + physical exercise) showed a reduced OD of TH+ fibers,
Main effects of MPTP (MPTP-treated mice without physical exercise vs. saline-treated mice without physical exercise) per brain area

| Brain area | Regulator(s) | Canonical pathway(s) | Biofunction(s) |
|------------|--------------|----------------------|----------------|
| SN         | CREB1        | △ Neuropathic pain signaling △ | Seizures Cognition △ |
| VTA        | CREB1, RICTOR | △ Protein synthesis △ | Movement disorder △ |
| DL         | bicuculline/dalfampridine, RICTOR | △ Mitochondrial dysfunction △ | Epilepsy △ |
| VM         | CREB1, bicuculline/dalfampridine | = N/A | Epilepsy △ |
| PFC        | bicuculline/dalfampridine | △ N/A | N/A |
| PPN        | L-DOPA       | △ Dopamine receptor signaling △ | Epilepsy △ |

For each of the effects, the corresponding z-score, a predicted direction of the effect, is displayed as increased (z-score ≥ 2; △), no significantly predicted direction (=) or decreased (z-score ≤ -2; △). "N/A": no significantly enriched canonical pathways or biofunctions for a brain area (p≥0.05).

no significant effects of MPTP, physical exercise, or their interaction were found.

qPCR Validation of the RNAseq Data

The RNAseq data were obtained from pooled samples, and in order to validate these data, the mRNA expression levels in each of the investigated brain areas were determined in individual samples by qPCR. The results of the qPCR experiments (Online Resource 4) led us to adopt the following requirements for the inclusion of differentially expressed protein-coding mRNAs in the subsequent analyses: FC > 1.2, likelihood ratio < 0.05, RPKM > 5.

A Direct Effect of Physical Exercise on MPTP-Regulated Genes

The overlap between the protein-coding mRNAs that are differentially expressed due to MPTP alone and due to exercise in MPTP-treated mice is represented in Online Resource 5. In all brain areas, the probability of this overlap was calculated by using the hypergeometric distribution test, which showed that for all areas, the overlap is greater than would be expected based on random gene selection (p < 0.05). Further, in all areas, 82–99% of the overlapping mRNAs are regulated in opposite directions by MPTP and exercise. Enrichment analysis of mRNAs that overlap but are regulated in opposite directions are summarized in Online Resource 10, Supp. Table 2. The VTA and PFC show the most significant results, and are also the brain areas with the biggest absolute and relative overlap (i.e., the overlap in number and proportion of mRNAs). The analysis of the VTA displays a downregulation of the top regulator “inosine”, whereas the PFC and to a lesser extent also the DL show an increase in effect of dalfampridine and bicuculline.

RNAseq Data Analysis: Enriched Regulators, Pathways, and Biofunctions

Enrichment analysis of the differentially expressed mRNAs was performed for each of the brain areas examined to investigate the effects of MPTP (i.e., comparing the MPTP-treated group without exercise to the saline-treated mice without exercise), physical exercise (i.e., comparing saline-treated mice with exercise to saline-treated mice without exercise), and the effects of physical exercise in MPTP-treated mice (i.e., comparing the MPTP-treated mice with exercise to MPTP-treated mice without exercise). In Tables 1, 2, and 3, a short overview of the main effects—the top regulator(s), canonical pathway(s), and biofunction(s)—of MPTP, physical exercise, and physical exercise in MPTP-treated mice is provided for each brain area separately. A more elaborate overview of these enrichment analyses per brain area can be found in Online Resource 10, Supp. Tables 3–8.

In all brain areas examined, MPTP treatment affected a set of mRNAs that is involved in epilepsy, which is reflected by the presence of the epilepsy-regulating transcription factor CREB1, the convulsants bicuculline and dalfampridine, and the biofunction “epilepsy”. Other regulators and related functional themes enriched within the mRNAs affected by MPTP are RICTOR and its regulation of ribosomal and mitochondrial proteins, as well as L-DOPA and DA receptor signaling (Table 1). Of note, in line with the MPTP-mediated decrease in TH expression in the DL and VM (not significant; see above), L-DOPA is a significant upstream regulator in both the DL (p = 2.85E-06; z = -2.635) and the VM (p = 9.97E-04; z = -1.234), but was not among the top 10 upstream regulators and is therefore not included in the (Supplementary) Tables. Furthermore, in the various brain areas examined, physical exercise affected sets of mRNAs that are regulated by the upstream regulators CREB1, RICTOR, L-
DOPA, and dexamethasone. These regulators overlap to some extent with the upstream regulators for the MPTP-regulated mRNAs as mentioned above. However, the top canonical pathways and biofunctions due to physical exercise are not epilepsy-related, but rather associated with “mitochondrial dysfunction” and “movement disorder” (Table 2).

The top regulators of the mRNAs differentially expressed due to physical exercise in MPTP-treated mice are L-DOPA, RICTOR, bicuculline/dalfampridine, and CREB1. The top canonical pathways and biofunctions enriched in exercised MPTP-treated mice are “mitochondrial dysfunction” and “protein synthesis” in the VTA and DL, “G-protein signaling”, “movement disorder”, “seizures and cytoskeleton dynamics” in the VM and are related to (cell) death in the PFC (Table 3).

Of note, the predicted direction of effect of the top regulators RICTOR and L-DOPA is changed in the VTA, DL, and VM of exercised MPTP-treated mice compared to exercised saline-treated mice. More specifically, the predicted direction of effect of RICTOR is (strongly) decreased in the VTA and DL after exercise in saline-treated mice, but is strongly increased and has no significant predicted direction in the VTA and DL of exercised MPTP-treated mice, respectively.

Table 2  Main effects of physical exercise (saline-treated mice with physical exercise vs. saline-treated mice without physical exercise) per brain area

| Brain area | Regulator(s) | Canonical pathway(s) | Biofunction(s) |
|------------|--------------|----------------------|----------------|
| SN         | CREB1        | =                    | Movement disorder |
|            |              |                      | Neurotransmission |
| VTA        | CREB1        | =                    | Seizures |
|            | RICTOR       | V                    |                |
| DL         | RICTOR       | =                    | Mitochondrial dysfunction |
|            |              |                      | Protein synthesis |
| VM         | L-DOPA       | =                    | Mitochondrial dysfunction |
|            |              |                      | Protein synthesis |
| PFC        | Dexamethasone |                      | Cell proliferation / cancer |
|            |              |                      | Mortality |
| PPN        | L-DOPA       | =                    | Movement disorder |
|            |              |                      | Development of neurons |

For each of the effects, the corresponding z-score, a predicted direction of the effect, is displayed as increased (z-score ≥ 2; V), no significantly predicted direction (=), decreased (z-score ≤ -2; V) or very much decreased (z-score ≤ -6; VV). “N/A”: no significantly enriched canonical pathways or biofunctions for a brain area (p≥0.05).

Table 3  Main effects of physical exercise in MPTP-treated mice (MPTP-treated mice with physical exercise vs. MPTP-treated mice without physical exercise) per brain area

| Brain area | Regulator(s) | Canonical pathway(s) | Biofunction(s) |
|------------|--------------|----------------------|----------------|
| SN         | L-DOPA       | =                    | N/A |
| VTA        | RICTOR       |                      | Mitochondrial dysfunction |
|            |              |                      | Protein synthesis |
| DL         | RICTOR       | =                    | Mitochondrial dysfunction |
|            |              |                      | Protein synthesis |
| VM         | L-DOPA       | VV                   | G-protein signaling |
|            |              |                      | Movement disorder |
|            |              |                      | Seizures |
|            |              |                      | Cytoskeleton dynamics |
|            |              |                      | Learning |
| PFC        | bicuculline/dalfampridine | 
|            |              |                      | RAR Activation |
|            |              |                      | Cell proliferation / cancer |
|            |              |                      | Epilepsy |
|            |              |                      | (cell) death |
| PPN        | CREB1        | =                    | N/A |

For each of the effects, the corresponding z-score, a predicted direction of the effect, is displayed as very much increased (z-score ≥ 6; ▲▲), increased (z-score ≥ 2; ▲), no significantly predicted direction (=), decreased (z-score ≤ -2; V) or very much decreased (z-score ≤ -6; VV). “N/A”: no significantly enriched canonical pathways or biofunctions for a brain area (p≥0.05).
Further, L-DOPA shows a strongly decreased predicted direction of effect in the VM of exercised MPTP-treated mice, whereas this direction of effect was absent after exercise alone.

The Main Molecular Pathways Regulated by Physical Exercise

To elucidate the main molecular pathways regulated by physical exercise in MPTP-treated mice, the mRNA sets regulated by the top upstream regulators L-DOPA (in the SN and VM, Online Resource 10, Supp. Tables 9 and 10), RICTOR (in the DL and VTA, Online Resource 10, Supp. Tables 11 and 12), bicuculline/dalfampridine (in the PFC, Online Resource 10, Supp. Table 13), and CREB1 (in the PPN, Online Resource 10, Supp. Table 14) were studied in greater detail and used to build molecular landscapes for each top upstream regulator in the various brain areas. Here, we provide a short description of each of these molecular landscapes. In Online Resource 10, all landscapes are described in full detail. Of note, in the PPN, L-DOPA is the top upstream regulator following physical exercise or MPTP treatment, but L-DOPA ($p = 1.97\times10^{-2}; z$ score $= -1.964$), although significant, was not among the top 10 upstream regulators following physical exercise in MPTP-treated mice.

The molecular landscapes of interacting proteins encoded by the L-DOPA-regulated mRNAs that are differentially expressed in the SN and the VM due to physical exercise in MPTP-treated mice, are shown in Figs. 4 and 5, respectively. In the SN landscape, G-coupled receptor signaling (involving the proteins ARRB2 and GRP39), glucose uptake and signaling (SLC2A1), DA signaling (PPP1R1B), and reactive oxygen species (ROS) regulation (HSPB6, FTL, ROMO1) converge on the activation of ERK1/2 (ACKR1, EDNRB, GPR39, IER3, TP53), apoptotic pathways (CASP3, TP53), CREB1, and circadian clock regulation (PER1, DBP, CIART) (Fig. 4). In the VM landscape, the main molecular pathways are (interneuron-mediated) DA release (involving the proteins CHAT, DOC2B, SYN1, and TH) and signaling (DRD2, PPP1R1B), cannabinoid signaling (CNR1, FAAH), and neuropeptide signaling (PDYN, PENK, TAC1) that subsequently regulate/activate ERK1/2, CREB1, and CCND1 signaling. The latter is a cell cycle regulator that may also be involved in synaptic plasticity and learning [43] (Fig. 5). Of note, almost all proteins in this landscape are regulated by physical exercise and L-DOPA in opposite directions.

The RICTOR-regulated mRNAs that are differentially expressed in the DL and VTA due to physical exercise in the MPTP-treated mice encode proteins that are specifically involved in three cellular systems: the complex I-V of PD. The direction of effect of physical exercise (measured) and L-DOPA (from literature) on the expression of these mRNAs is depicted through colored borders. L-DOPA-activated proteins are shown with purple writing for the protein name, and familial PD proteins are shown with a blue border.
the electron transport chain, the 40S and 60S ribosomal subunits, and the proteasome (see Online Resource 10, Supp. Tables 11 and 12). These are complexes that regulate cellular energy, protein translation, and protein degradation, respectively (Online Resources 6 and 7). Of note, physical exercise and RICTOR have an opposite effect on the expression of all differentially expressed mRNAs in the mitochondrial electron transport chain in the DL, whereas physical exercise and RICTOR exert the same direction of effect (i.e., a decreasing effect) on the expression of electron transport chain mRNAs in the VTA.

In the PFC, 8 out of 9 mRNAs differentially expressed due to physical exercise in MPTP-treated mice and regulated by bicuculline/dalfampridine have been linked to epilepsy (Online Resource 10, Supp. Table 13). Immediate-early gene activation is one of the main processes regulated by these mRNAs e.g., via the early response genes/proteins FOS, FOSB, and NR4A1, which in turn are regulated by insulin and low-density lipoprotein. In Online Resource 8, an overview of the interactions of the proteins encoded by these mRNAs and their regulation by bicuculline/dalfampridine and physical exercise is shown in a molecular landscape.

In the PPN, the proteins encoded by the mRNAs that were differentially expressed due to physical exercise in MPTP-treated mice and regulated by CREB1 have only a limited number of interactions in the built landscape (Online Resource 9). Nevertheless, a few functional themes such as vascular remodeling, neuropeptide signaling, lipid metabolism, epilepsy/immediate-early gene regulation, and calcium signaling were identified, with CREB1 as their central regulator (Online Resource 10, Supp. Table 14).

**Discussion**

This study aimed to explore the molecular mechanisms underlying the beneficial effects of physical exercise on motor functioning in the MPTP-treated mouse model of PD. After validation of the model, through demonstrating significant nigral neuronal loss following MPTP treatment, the effects of a four-week physical exercise regimen on motor performance, and
the accompanying molecular changes in multiple brain areas were assessed using behavioral tests and RNAseq analysis, respectively. The behavioral tests showed that physical exercise improved beam walk and rotarod performance in both MPTP-treated and control mice, but had a different and often opposite effect on the four tested open field parameters in these groups. Our RNAseq findings demonstrated that physical exercise in MPTP-treated mice mainly affects the expression of mRNAs involved in L-DOPA-mediated pathways in the SN and VM that regulate DA signaling, RICTOR-mediated pathways in the VTA and DL involved in energy metabolism and cellular stress [44, 45], and bicuculline/dalfampridine-mediated pathways in the PFC and CREB1-mediated pathways in the PPN that are both a measure of neuronal activity [46, 47]. To further elucidate the specific molecular mechanisms underlying the effects of physical exercise in MPTP-treated mice, the differentially expressed mRNAs regulated by these top regulators were integrated into molecular landscapes, depicting the main biological processes and signaling cascades affected.

Our animal model was validated by demonstrating a significant nigral DA neuronal loss following MPTP treatment. The observed moderate neuronal loss in the midbrain due to MPTP treatment, i.e., a 29% reduction of TH-positive neurons in the SNpc without a statistical significant loss in the VTA, is in keeping with earlier studies using a similar MPTP treatment regimen in 5-month-old mice showing 33% loss in the SNpc and no significant loss in the VTA [48]. Other studies, on 8–10-week-old mice, have reported a neuronal loss of 29–45% [49, 50], but also of more than 50% loss in the SNpc [7, 24, 51]. Differences in level of neurodegeneration [52] and molecular effects [39] due to MPTP toxicity may be explained by MPTP dosing, age of the mice, and the duration between MPTP injection and sacrifice [48, 52]. We used aged (6-month-old) mice to better model age-dependent processes such as regulation of anti-oxidants [53], neuroplasticity, neurogenesis [54, 55], and the immune response in PD [56, 57]. To assess how exercise may boost any neuroplastic mechanisms of the injured basal ganglia, the physical exercise regime was performed within the recovery phase of striatal DA levels as reported in younger MPTP-treated mice [58], but after the acute neurotoxic (molecular) effects of MPTP [39, 59]. We did not find a significant effect of physical exercise on the number of surviving DA neurons, but noted a trend towards an increased number of TH-positive neurons in the SNpc and an increased TH-positive fiber density in the DL and VM in MPTP-treated mice with physical exercise compared to MPTP-treated mice without exercise. From previous studies, it remains unclear whether physical exercise can protect against cellular loss in the MPTP-mouse model. Preservation of SNpc neurons by physical exercise has been described before [27, 51], but the findings were inconsistent [7, 22].

Regarding motor function, forced exercise has more effect than voluntary exercise in both PD patients [60] and mice [61], and it activates the same brain areas as anti-PD medication does [62]. In this study, the mice were able to perform the physical exercise without any noticeable problems, suggesting that their physical exercise regimen is comparable to the forced moderate aerobic exercise that has been shown to improve both motor and non-motor functions in PD patients [11, 60, 63, 64]. MPTP treatment alone resulted in an increased activity in the open field, as reported before [48, 52, 65–67], but did not affect the performance on beam walk and rotarod. It should be noted that the training effect on the beam walk as seen in all four treatment groups, especially in week 1 compared to week 0, may implicate the necessity for more extensive training of the mice before the beam walk task in week 0. Further, the effects of exercise on the motor performance included an improvement on the beam walk and rotarod in both saline and MPTP-treated groups. However, the effects of physical exercise on the open field parameters in saline-treated mice was either absent or opposite in MPTP-treated animals. These findings suggest that some effects of physical exercise may be dependent on the “disease-state” (i.e., saline- or MPTP-treated). It could be argued, however, that the lack of effect of physical exercise in MPTP-treated mice on total walking distance and mean velocity (Fig. 2) may be due to their MPTP-induced hyperactivity (Fig. 1) that could have limited a further increase in motor performance due to physical exercise. This hyperactivity has been observed more often following MPTP treatment [48, 65, 66, 68–70] and may result from compensatory effects induced by e.g., brain areas of the mesolimbic pathway (see also below). Furthermore, the opposite effect of exercise on total movement time and mean angular velocity in MPTP-treated mice (Fig. 2) compared to the effect of MPTP alone (Fig. 1) suggests that physical exercise counteracts the effect of MPTP. This finding could have important translational value as axial symptoms in PD—such as hypokinetic rigidity which is reflected by reduced angular velocity [71–73]—are notoriously more difficult to treat by medication than appendicular symptoms.

The RNAseq analysis showed that the level of overlap between MPTP-regulated genes and physical exercise-regulated genes differed between the brain areas studied and was particularly high in the PFC and VTA. These data suggest that in the PFC and VTA, physical exercise influences the processes affected by MPTP more directly than in the other areas in which more indirect mechanisms may prevail. Nevertheless, in all brain areas examined, the majority of overlapping genes (82–99%) were regulated in opposite directions by physical exercise compared to MPTP, suggesting counteracting effects of physical exercise on MPTP-regulated mechanisms. For example, the enrichment analysis of the overlapping genes in the PFC and DL (see Online Resource 10, Supp. Table 2) shows a predicted activation of...
the top regulators dalfampridine, bicuculline, and CREB1—indicative for neuronal activation [46, 47]—whereas these are inactivated by MPTP.

The roles of the PD-related brain areas examined in this study can be summarized in a simplified basal ganglia circuitry model, wherein PPN, SN, and DL are mainly involved in motor control, and the VTA, VM, and PFC contribute particularly to the regulation of (complex) behavior and cognition (Fig. 6) [74–79]. The top regulators—and to a lesser extent also the canonical pathways and biofunctions—regulated by physical exercise in the cognition-associated brain areas of MPTP-treated mice, showed highly significant predicted directions of effect, whereas these effects were less prominent in the motor-related areas. This implicates that, although physical exercise is able to improve motor function (as supported by the behavioral tests), it may also have strong effects on cognition and behavior. This is interesting from a therapeutic point of view, because non-motor symptoms in PD patients—including cognitive impairment, depression, pain, and sleep disorders—are usually less responsive to dopamine replacement therapy and therefore treatment options are limited [80–82]. It remains unclear, however, to what extent these motor and non-motor features of PD have truly discernible neuroanatomical or molecular substrates, as effects of changes in mRNA expression in the “behavioral areas” VTA, VM, and PFC on motor function of our animals cannot be excluded. For example, a recent paper reported that VTA-specific knockout of RICTOR in mice may affect cognition and mood, but also results in hyperactivity in the open field [83]. In addition, it has been suggested that during exercise, the mesolimbic pathway (including the VTA and VM) may provide a compensatory functional activation of the motor loop [84]. Furthermore, whereas L-DOPA is known to improve DL-mediated motor symptoms, it may impair VM function in PD patients [85, 86]. Therefore, exercise may counteract L-DOPA-mediated pathways in the VM and as such improve VM functionality, which could in turn result in increased compensatory motor-loop activation. Finally, inhibition of GABAergic interneurons in the PFC by bicuculline increases the release of DA in the DL through the glutamatergic corticostriatal pathway [87–89] and may increase the locomotor activity of mice [88, 90]. This is in line with the reduced TH expression we observed in the DL and the inactivation of bicuculline/dalfampridine-regulated pathways in the PFC following MPTP treatment, as predicted on the basis of the RNAseq analysis. Moreover, we found no significantly reduced TH expression in the DL of exercised MPTP-treated mice that, in contrast to MPTP-treated mice without exercise, showed a predicted activation of the bicuculline/dalfampridine-regulated pathways in the PFC.

Almost five decades after its introduction [4], the DA precursor L-DOPA is still the gold standard for symptomatic treatment to alleviate the motor symptoms of PD [5]. It should be noted, however, that chronic high-dose L-DOPA use is associated with complications such as dyskinesias [91–93]. Moreover, the effects of L-DOPA on non-motor symptoms in PD are even less predictable and L-DOPA use may even lead to deterioration of these symptoms, e.g., impaired reversal learning or motor sequence learning deficits [94–101]. It has been suggested that these adverse cognitive effects of L-DOPA may be due to a higher L-DOPA demand in the motor systems compared to cognitive areas, resulting in a relative L-DOPA overdose in cognitive areas [102–104] e.g., the VM (see also above). Therefore, novel “add-on” treatments that can enable low-dose L-DOPA use and/or reduce the adverse effects of (long-term) L-DOPA use are desirable. In this

Fig. 6 Overview of the brain areas analyzed, and the top upstream regulators, and processes per area. The brain areas are shown in a simplified model of the basal ganglia circuitry. Green, red, and gray triangles depict positive (> 2), negative (< −2) or non-significant z scores, respectively, from the enrichment analyses of the physical exercise-regulated mRNAs in MPTP-treated mice. DL dorsolateral striatum, GPe globus pallidus external, GPi globus pallidus internal, PFC prefrontal cortex, PPN pedunculopontine nucleus, SNpc substantia nigra pars compacta, SNr substantia nigra reticularis, STN subthalamic nucleus, VM ventromedial striatum, VTA ventral tegmental area
respect, our study suggests that physical exercise is an attractive add-on treatment for PD, and that exercise combined with L-DOPA treatment may be more beneficial than treatment of PD patients with L-DOPA alone [9, 105]. Other findings that support this hypothesis include the reports indicating that physical exercise not only improves the motor symptoms of PD patients [8, 9], but also L-DOPA-induced dyskinesias in PD patients [106] and animal models [107], and cognitive function in PD patients [2, 16, 17]. In this light, it is of note that L-DOPA use may result in alpha-synuclein-induced neuroinflammation [108] that very recently has been shown to be reduced by physical exercise [109–111]. Although the major pathways regulated in our study are not directly related to inflammation, L-DOPA-mediated pathways may affect alpha-synuclein regulation [108], and the RICTOR-regulated pathways may improve mitochondrial function and protein turn-over, i.e., processes that have been suggested to reduce alpha-synuclein-induced neuroinflammation [111].

Considering the above, it is worth noting that our landscapes revealed that physical exercise and L-DOPA regulate similar pathways in the SN and VM—often in an opposite direction—and that most of these pathways have been linked to sleeping problems (SN) and cognitive and/or motor dysfunctioning (VM) in PD. For example, the expression of clock proteins was affected by physical exercise and L-DOPA in the SN, a brain region known to be involved in the regulation of REM sleep [112, 113] and causing circadian rhythm irregularities when damaged by MPTP [114, 115]. Further, the use of L-DOPA can disturb REM sleep [116] and result in a delayed sleep onset in PD patients, which suggests an uncoupling of sleep and circadian regulation [117]. On the other hand, physical exercise can improve circadian rhythm regulation [118–120] and may therefore serve as a complementary therapy to strengthen circadian function in PD, as suggested earlier [121].

In the VM, both physical exercise and L-DOPA regulate DA, neuropeptide, and endocannabinoid signaling, but in opposite directions. L-DOPA treatment results in sustained DA signaling in the striatum and can disrupt DA and (endo)cannabinoid receptor crosstalk [122, 123]. In contrast, physical exercise may rebalance DA signaling after sustained L-DOPA treatment (by reducing PPP1R1B activation) [107], attenuates depression-like behavior by decreasing the expression of neuropeptides [124] and activates the endocannabinoid system [125–127]. In turn, the endocannabinoid system modulates synaptic (DA) transmission in the striatum of PD patients [128–130], restores homeostasis following DA depletion [131, 132] and exerts beneficial effects on cognition, mood, and nociception [126]. Therefore, physical exercise seems to exert a positive effect on the regulation of DA, neuropeptide, and endocannabinoid signaling. Moreover, these three signaling pathways are not only associated with L-DOPA-induced dyskinesia [133–138], a process that is mainly due to dysregulation in the DL, but are also involved in regulating VM-associated cognitive functions and behaviors [124, 139–144], supporting the notion that the anatomical and neurophysiological boundaries of the striatal domains regulating control of movement (DL) and (more) cognition-related processes (VM) may functionally overlap [145, 146].

In summary, the molecular pathways that are regulated in the SN and VM by both physical exercise and L-DOPA can be directly linked to clinical features of PD. Interestingly, the overall effects of physical exercise on these pathways seem to particularly improve the motor and behavioral clinical phenotype, whereas (chronic) L-DOPA-treatment can also cause adverse effects. Moreover, to our knowledge, physical exercise exerts—although it may counteract some L-DOPA-regulated pathways—no adverse effects on PD patients. To confirm the positive effects of physical exercise on cognitive function, future physical exercise studies in PD animal models and patients should include cognitive tests, e.g., the Y-maze, the water maze, or reversal learning tasks. Furthermore, these studies should aim at further elucidating the molecular pathways underlying physical exercise in relation to (chronic) L-DOPA treatment in animal models.

Taken together, our findings provide further evidence that physical exercise improves motor function in PD, while it also affects the regulation of non-motor brain areas of MPTP-treated mice. We found that physical exercise and L-DOPA exert opposite effects on molecular pathways in several PD-associated brain areas, including those involved in sleeping and cognitive function. Overall, the present study suggests that physical exercise has therapeutic potential, not only to improve motor function but it may also improve non-motor symptoms of PD—and perhaps even alleviate detrimental effects associated with (chronic) L-DOPA use.

**Funding** Author J.E. Visser was supported by Stichting Parkinsonfonds, The Netherlands Organization for Scientific Research (NWO/ZonMw, VENI 916.12.167) and The Netherlands Brain Foundation (F2014(1)-16).

**Compliance with Ethical Standards** All animal experiments were approved by the Animal Care Committee of the Radboud University Nijmegen Medical Center, The Netherlands, and performed according to the guidelines of the Dutch Council for Animal Care and the European Communities Council Directive 2010/63/EU.

**Conflict of Interest** The authors declare that they have no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170

2. David FJ, Robichaud JA, Leurgans SE, Poon C, Kohrt WM, Goldstein JG et al (2015) Exercise improves cognition in Parkinson’s disease: The PRET-PD randomized, clinical trial. Mov Disord 30(12):1657–1663

3. Sveinbjörnsdottrí S (2016) The clinical symptoms of Parkinson’s disease. J Neurochem 139(Suppl 1):318–324

4. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276(7):374–379

5. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho Y (2015) Effects of dance on motor functions, cognitive functions, and mental symptoms of Parkinson’s disease: a quasi-randomized pilot trial. Complement Ther Med 23(2):210–219

6. Reynolds GO, Otto MW, Ellis TD, Cronin-Golomb A (2016) The therapeutic potential of exercise to improve mood, cognition, and sleep in Parkinson’s disease. Mov Disord 31(1):23–38

7. Petzinger GM, Walsh JP, Akopian G, Hogg E, Abernathy A, Arevalo P et al (2007) Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J Neurosci Off J Soc Neurosci 27(20):5291–5300

8. Cizadlo TM, Newhouse DJ (2006) Is physical exercise beneficial for persons with Parkinson’s disease? Clin J Sport Med 16(5):422–425

9. Muller T, Muhsack S (2010) Effect of exercise on reactivity and motor behaviour in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 81(7):747–753

10. Wu PL, Lee M, Huang TT (2017) Effectiveness of physical activity and exercise interventions for Parkinson’s disease. Mov Disord 32(4):514–518

11. Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt TD (2016) The clinical symptoms of Parkinson’s disease. J Neurochem 139(Suppl 1):318–365

12. Ridgel AL, Peacock CA, Fickes EJ, Kim CH (2012) Active-

13. Klamroth S, Steib S, Devan S, Pfeifer K (2016) Effects of exercise therapy on postural instability in Parkinson disease: a meta-analysis. J Neurol Phys Ther 40(1):3–14

14. Hashimoto H, Takahatake S, Miyaguchi H, Nakaniishi H, Naitou Y (2015) Effects of dance on motor functions, cognitive functions, and mental symptoms of Parkinson’s disease: a quasi-randomized pilot trial. Complement Ther Med 23(2):210–219

15. Churchill MJ, Pihlens L, Sconce MD, Moore C, Kim K, Meshul CK (2017) Exercise in an animal model of Parkinson’s disease: Motor recovery but not restoration of the nigrostriatal pathway. Neuroscience 359:224–247

16. Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul CK et al (2004) Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res 77(3):378–390

17. Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2(1):141–151

18. Meredith GE, Rademacher DJ (2011) MPTP mouse models of Parkinson’s disease: an update. J Park Dis 1(1):9–33

19. Archer T, Fredriksson A (2010) Physical exercise attenuates MPTP-induced deficits in mice. Neurotox Res 18(3–4):313–327

20. Fredriksson A, Stigsdotter IM, Hurtig A, Ewals-Kvist B, Archer T (2011) Running wheel activity restores MPTP-induced functional deficits. J Neural Transm 118(3):407–420

21. Lau YS, Patki G, Das-Panja K, Le WD, Ahmad SO (2011) Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson’s disease with moderate neurodegeneration. Eur J Neuropsi 33(7):1264–1274

22. Aguiar AS Jr, Lopes SC, Tristao FS, Rial D, de Oliveira G, da Cunha C et al (2016) Exercise improves cognitive impairment and dopamine metabolism in MPTP-treated mice. Neurotox Res 29(1):118–125

23. Churchill MJ, Pihlens L, Sconce MD, Moore C, Kim K, Meshul CK (2017) Exercise in an animal model of Parkinson’s disease: Motor recovery but not restoration of the nigrostriatal pathway. Neurosci 359:224–247

24. Fisher BE, Petzinger GM, Nixon K, Hogg E, Bremmer S, Meshul CK et al (2004) Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia. J Neurosci Res 77(3):378–390

25. Smith BA, Goldberg NR, Meshul CK (2011) Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse. Brain Res 1386:56–577

26. Smith BA, Goldberg NR, Meshul CK (2011) Effects of treadmill exercise on behavioral recovery and neural changes in the substantia nigra and striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse. Brain Res 1386:70–80

27. Carter RJ, Leone LA, Humby T, Mangiarini L, Mahal A, Bates GP et al (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci Off J Soc Neurosci 19(8):3248–3257

28. Klivenyi P, Bende Z, Hartai Z, Penke Z, Nemeth H, Toldi J et al (2006) Behaviour changes in a transgenic model of Huntington’s disease. Behav Brain Res 169(1):137–141

29. Pang TY, Stamm NC, Nithanantharajah J, Howard ML, Hannan AJ (2006) Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington’s disease transgenic mice. Neuroscience 141(2):569–584

30. Jansen D, Zerbi V, Arnoldussen IA, Wiesmann M, Ripjama A, Fang XT et al (2013) Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuroplasticity in AbetaPPswe-PS1dE9 mice. PLoS ONE 8(9):e75393

31. Jansen CI, Zerbi V, Mutsaers MP, de Jong BS, Wiesmann M, Arnoldussen IA et al (2015) Impact of dietary n-3 polyunsaturated fatty acids on cognition, motor skills and hippocampal neurogenesis in developing C57BL/6J mice. J Nutr Biochem 26(1):24–35

32. Carter RJ, Morton J, Dunnett SB (2001) Motor coordination and balance in rodents. Curr Protoc Neurosci 15:8.12:8.12.1

33. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP et al (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington’s disease mutation. J Neurosci Off J Soc Neurosci 19(8):3248–3257

34. Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY et al (2006) Behaviour changes in a transgenic model of Huntington’s disease. Behav Brain Res 169(1):137–141

35. Pang TY, Stamm NC, Nithanantharajah J, Howard ML, Hannan AJ (2006) Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington’s disease transgenic mice. Neuroscience 141(2):569–584

36. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676–682

37. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9(7):676–682
37. Olde Looijens NF, Kole K, Glennon JC, Karel P, Van der Borg G, Van Gennip Y et al (2015) Elevated microRNA-181c and microRNA-30d levels in the enlarged amygdala of the valproic acid rat model of autism. Neurobiol Dis 80:42–53
38. Wu WS, Li WH (2008) Systematic identification of yeast cell cycle transcription factors using multiple data sources. BMC Bioinformatics 9:522
39. Poelmans GJM, Martens GMJ, Poelmans G, Visser JE (2016) Validity of the MPTP-treated mouse as a model for Parkinson's disease. Mol Neurobiol 53(3):1625–1636
40. Poelmans G, Pauls DL, Buitelaar JK, Franke B (2011) Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry 168(4):365–377
41. Poelmans G, Franke B, Pauls DL, Glennon JC, Buitelaar JK (2013) AKAPs integrate genetic findings for autism spectrum disorders. Transl Psychiatry 3:e270
42. Klemann CJHM, Martens GMJ, Sharma M, Martens MB, Isacson O, Gasser T et al (2017) Integrated molecular landscape of Parkinson's disease. NPJ Park Dis 3:14
43. Wu K, Li S, Bodhinathan K, Meyers C, Chen W, Campbell-Moore AN, Waxham MN, Dash PK (1996) Neuronal activity signaling through GSK-3beta-mediated phosphorylation of rictor. AK, Lee SW et al (2011) ER stress inhibits mTORC2 and Akt
44. UniProt (2015) UniProt: a hub for protein information. Nucleic Acids Res 43(Database issue):D204–D212
45. Chen CH, Shaikenov T, Peterson TR, Aimbetov R, Bissenbaev AK, Lee SW et al (2011) ESF stress inhibits mTORC2 and Akt signaling through GSK-3-beta-mediated phosphorylation of rictor. Sci Signal 4(163):ra10
46. Moore AN, Waxham MN, Dash PK (1996) Neuronal activity increases the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in rat hippocampus and cortex. J Biol Chem 271(24):14214–14220
47. Beaumont TL, Yao B, Shah A, Kapatos G, Loeb JA (2012) Layer-specific CREB target gene induction in human neocortical epilepsy. J Neurosci Off J Soc Neurosci 32(41):14389–14401
48. Rousselet E, Joubert C, Callebert J, L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Serapide M (2008) Effects of aging on neuroprotective and neurotoxic properties of microglia in neurodegenerative diseases. Neurodegener Dis 3(3–4):254–256
49. Munoz-Manchado AB, Villadiego J, Romo-Madero S, Suarez-Luna N, Bermejo-Navas A, Rodriguez-Gomez JA et al (2016) Chronic and progressive Parkinson's disease MPTP model in adult and aged mice. J Neurochem 136(2):373–387
50. Jakowec MW, Nixon K, Hogg E, McNeill T, Petzinger GM (2004) Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway. J Neurosci 76(4):539–550
51. Vila M, Jackson-Lewis V, Yukovskia S, Djaldetti R, Liberator G, Offen D et al (2001) Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 98(5):2837–2842
52. Ridgel AL, Vitek JL, Alberts JL (2009) Forced, not voluntary, exercise improves motor function in Parkinson's disease patients. Neurorehabil Neural Repair 23(6):600–608
53. Gorton LM, Vuckovic MG, Vertelkina N, Petzinger GM, Jakowec MW, Wood RI (2010) Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse. Behav Brain Res 213(2):253–262
54. Alberts JL, Phillips M, Lowe MJ, Frankenollette A, Thota A, Beall EB et al (2016) Cortical and motor responses to acute forced exercise in Parkinson's disease. Parkinsonism Relat Disord 24:56–62
55. Shu HF, Yang T, Yu SX, Huang HD, Jiang LL, Gu JW et al (2014) Aerobic exercise for Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. PLoS One 9(7):e100503
56. Dora CE, Scheck KC, Magnotta V, Dawson JD, Thomsen TR, Kline JN et al (2014) Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting. Neurology 83(5):413–425
57. Luchtman DW, Meng Q, Song C (2012) Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav Brain Res 226(2):386–396
58. Wang H, Liang X, Wang X, Luo D, Jia J, Wang X (2013) Electro-acupuncture stimulation improves spontaneous locomotor hyperactivity in MPTP intoxicated mice. PLoS One 8(5):e64403
59. Ferguson SA, Law CD, Sarkar S (2015) Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment. Behav Brain Res 292:68–78
60. Colotla VA, Flores E, Osco A, Meneses A, Tapia R (1999) Effects of MPTP on locomotor activity in mice. Neurotoxicology Teratol 21(4):405–407
61. Chia LG, Ni DR, Cheng FC, Ho YP, Kuo JS (1999) Intrastriatal injection of 5,7-dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice. Neurochem Res 24(6):719–722
62. Luchtman DW, Shao D, Song C (2009) Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav 98(1–2):130–138
63. Visser JE, Voermans NC, Oude Nijhuis LB, van der Eijk M, Nijk R, Munneke M et al (2007) Quantification of trunk rotations during turning and walking in Parkinson's disease. Clin Neurophysiol 118(7):1602–1606
72. Tabbald SD, Ushe M, Mink JW, Revilla FJ, Wemle AR, Hong M et al (2008) Unilateral subthalamic nucleus stimulation has a measurable ipsilateral effect on rigidity and bradykinesia in Parkinson disease. Exp Neurol 211(1):234–242
73. Godoy R, Noble S, Yoon K, Anisman H, Ekker M (2015) Chemogenetic ablation of dopaminergic neurons leads to transient locomotor impairments in zebrafish larvae. J Neurochem 135(2):249–260
74. Alexander GE (1994) Basal ganglia-thalamocortical circuits: their role in control of movements. J Clin Neurophysiol 11(4):420–431
75. Herrero MT, Barcia C, Navarro JM (2002) Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst 18(8):386–404
76. Cools R (2008) Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist 14(4):381–395
77. Leisman G, Braun-Benjamin O, Melillo R (2014) Cognitive-motor interactions of the basal ganglia in development. Front Syst Neurosci 8:16
78. Haber SN (2014) The place of dopamine in the cortico-basal ganglia-thalamus and basal ganglia. Childs Nerv Syst 18(8):386–404
79. Morita H, Hass CJ, Moro E, Sudhyadhom A, Kumar R, Okun MS (2014) Pedunculopontine nucleus stimulation: where are we now and what needs to be done to move the field forward? Front Neurol 5:243
80. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464–474
81. Wood LD, Neumiller JJ,Setter SM, Dobbins EK (2010) Clinical review of treatment options for select nonmotor symptoms of Parkinson’s disease. Am J Geriatr Pharmacother 8(4):294–315
82. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzschnegler R et al (2011) The Movement Disorder Society evidence-based medicine review update: treatments for the nonmotor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80
83. Kaska S, Brunk R, Bali V, Kechner M, Mazei-Robison MS (2017) Deletion of Rictor in catecholaminergic neurons alters locomotor activity and ingestive behavior. Neuropharmacology 117:158–170
84. Nozaki T, Sugiyama K, Yagi S, Yoshikawa E, Kanno T, Asakawa T et al (2013) Effect of subthalamic nucleus stimulation during exercise on the mesolimbic-cortical dopaminergic region in Parkinson’s disease: a positron emission tomography study. J Cereb Blood Flow Metab 33(3):415–421
85. MacDonald PA, MacDonald AA, Seergobin KN, Tamjidee R, Ganjavi H, Provost JS et al (2011) The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson’s disease: support from functional MRI. Brain 134( Pt 5):1447–1463
86. Yang W, Liu B, Huang B, Huang R, Wang L, Zhang Y et al (2016) Altered resting-state functional connectivity of the striatum in Parkinson’s disease after levodopa administration. PLoS One 11(9):e0161935
87. Karler R, Calder LD, Thai DK, Bedingfield JB (1998) The role of dopamine and GABA in the frontal cortex of mice in modulating a motor-stimulant effect of amphetamine and cocaine. Pharmacol Biochem Behav 60(1):237–244
88. Matsumoto M, Kanno M, Togashi H, Ueno K, Otani H, Mano Y et al (2003) Involvement of GABA receptors in the regulation of the prefrontal cortex on dopamine release in the rat dorsolateral striatum. Eur J Pharmacol 482(1–3):177–184
89. Jiao D, Liu Y, Li X, Liu J, Zhao M (2015) The role of the GABA system in amphetamine-type stimulant use disorders. Front Cell Neurosci 9:162
90. Bubser M, Fenstra MG, Erdtsieck-Ernte EB, Botterblom MH, Van Uum HF, Pool CW (1997) Modulatory role of catecholamines in the transsynaptic expression of c-fos in the rat medial prefrontal cortex induced by disinhibition of the mediiodorsal thalamus: a study employing microdialysis and immunohistochemistry. Brain Res 749(2):214–225
91. Picconi B, Paille V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS et al (2008) L-DOPA dosage is critically involved in dyskinesia via loss of synaptic potentiation. Neurobiol Dis 29(2):327–335
92. Jennner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665–677
93. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B (2010) Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to bedside gap. Lancet Neurol 9(11):1106–1117
94. Gotham AM, Brown RG, Marsden CD (1988) ‘Frontal’ cognitive function in patients with Parkinson’s disease ’on’ and ‘off’ levodopa. Brain 111( Pt 2):299–321
95. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW (2000) Probabilistic learning and reversal deficits in patients with Parkinson’s disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 38(5):596–612
96. Cools R, Barker RA, Sahakian BJ, Robbins TW (2001) Enhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demands. Cereb Cortex 11(12):1136–1143
97. Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW (2007) L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson’s disease. Neuropsychopharmacology 32(1):180–189
98. Cools R, Barker RA, Sahakian BJ, Robbins TW (2003) L-Dopa medication remedies cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia 41(11):1431–1441
99. Kwak Y, Muller ML, Bohnen NI, Dayalu P, Seidler RD (2012) L-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson’s disease. Behav Brain Res 230(1):116–124
100. Nombela C, Rittman T, Robbins TW, Rowe JB (2014) Multiple modes of impulsivity in Parkinson’s disease. PLoS One 9(1):e85747
101. Calabresi P, Ghiglieri V, Mazzocchetti P, Corbelli I, Picconi B (2015) Levodopa-induced plasticity: a double-edged sword in Parkinson’s disease? Philos Trans R Soc Lond B Biol Sci. 370(1672). pii: 20140184
102. Kehagia AA, Barker RA, Robbins TW (2013) Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis 11(2):53
103. Vaillancourt DE, Schonfeld D, Kwak Y, Bohnen NI, Seidler RD (2012) L-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson’s disease. Behav Brain Res 230(1):116–124
104. Vo A, Seergobin KN, Morrow SA, MacDonald PA (2016) Levodopa impairs probabilistic reversal learning in healthy young adults. Psychopharmacology 233(14):2753–2763
105. Muhlac S, Welmic J, Woitall D, Muller T (2007) Exercise improves efficacy of levodopa in patients with Parkinson’s disease. Mov Disord 22(3):427–430
106. Frazzitta G, Bertotti G, Morelli M, Riboldazz G, Pelosin E, Balbi P et al (2012) Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. NeuroRehabilitation 30(4):295–301
107. Aguiar AS Jr, Moreira EL, Hoeller AA, Oliveira PA, Cordova FM, Glaser V et al (2013) Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice. Neuroscience 243:46–53
108. Lee HJ, Baek SM, Ho DH, Suk JE, Cho ED, Lee SJ (2011) Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp Mol Med 43(4):216–222

@ Springer
109. Jang Y, Koo JH, Kwon I, Kang EB, Um HS, Soya H et al (2015) Neuroprotective effects of endurance exercise against neuroinflammation in MPTP-induced Parkinson's disease mice. Brain Res 2017:186–193

110. Koo JH, Jang YC, Hwang DJ, Um HS, Lee NH, Jung JH et al (2017) Treadmill exercise produces neuroprotective effects in a murine model of Parkinson's disease by regulating the TLR2/MyD88/NF-kappaB signaling pathway. Neuroscience 356:102–113

111. Koo JH, Cho JY (2017) Treadmill exercise attenuates alpha-synuclein levels by promoting mitochondrial function and autophagy possibly via SIRT1 in the chronic MPTP/P-induced mouse model of Parkinson's disease. Neurotox Res. https://doi.org/10.1007/s12004-017-0077-5

112. Lima MM, Andersen ML, Reksidler AB, Vital MA, Tufik S, Koo JH, Cho JY (2017) Treadmill exercise attenuates alpha-synuclein levels by promoting mitochondrial function and autophagy possibly via SIRT1 in the chronic MPTP/P-induced mouse model of Parkinson's disease. Neurotox Res. https://doi.org/10.1007/s12004-017-0077-5

113. Lima MM (2013) Sleep disturbances in Parkinson's disease: the contribution of dopamine in REM sleep regulation. Sleep Med Rev 17(5):367–375

114. M. Tanaka M, Yamaguchi E, Takahashi M, Hashimura K, Shibata T, Mol Neurobiol (2018) 55:5639

115. Hayashi A, Matsunaga N, Okazaki H, Kakimoto K, Kimura Y, Azuma H et al (2013) A disruption mechanism of the molecular clock in skeletal muscle. Med Sci Sports Exerc 45(9):2156–2160

116. Alatriste-Booth V, Rodriguez-Violante M, Camacho-Ordonez A, Cervantes-Arriaga A, Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, Perez-Martin J, Calabresi P (2008) The endocannabinoid system in Parkinson's disease. Neuron 590(23):215–225

117. Bilkei-Gorzo A, Racz I, Michel K, Zimmer A (2002) Diminished TLR2/MyD88/NF-κB signaling pathway. Neuroscience 99(3):675–681

118. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA (2012) VDOPA-treatment in primates disrupts the expression of A2A adenosine-CB(1) cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus. Neuropharmacology 79:620–627

119. Wolfe G, Esser KA (2012) Scheduled exercise phase shifts the circadian clock in skeletal muscle. Med Sci Sports Exerc 44(9):1670–1673

120. Schroeder AM, Truong D, Loh DH, Jordan MC, Roos KP, Colwell CS (2012) Voluntary scheduled exercise alters diurnal rhythms of behaviour, physiology and gene expression in wild-type and vasoactive intestinal peptide-deficient mice. J Physiol 590(23):6213–6226

121. Harrington ME (2012) Exercise strengthens circadian clocks. J Physiol 590(23):5929–5939

122. Bonaventura J, Rico AJ, Moreno E, Sierra S, Sanchez M, Luquin N et al (2014) L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus. Neuropharmacology 97:90–100

123. Pinna A, Bonaventura J, Farre D, Sanchez M, Simola N, Mallol J et al (2014) L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies. Exp Neurol 253:180–191

124. Bilkei-Gorzo A, Racz I, Michel K, Zimmer A (2002) Diminished anxiety- and depression-related behaviors in mice with selective deletion of the Tac1 gene. J Neurosci Off J Soc Neurosci 22(22):10046–10052

125. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A (2003) Exercise activates the endocannabinoid system. Neureport 14(17):2209–2211

126. Tanimonomo M, Ceci R, Sabatini S, Catani MV, Rossi A, Gasperi V et al (2014) Physical activity and the endocannabinoid system: an overview. Cell Mol Life Sci 71(14):2681–2698

127. Brellethagen AG, Crombie KM, Hillard CJ, Koltyn KF (2016) Endocannabinoid responses to exercise in low, moderate, and high active individuals: 3765 board #204 June 4, 8:00 AM - 9:30 AM. Med Sci Sports Exerc 48(5 Suppl 1):1052–1053

128. Di Filippo M, Piccioni B, Tozzi A, Ghiglieri V, Rossi A, Calabresi P (2008) The endocannabinoid system in Parkinson’s disease. Curr Pharm Des 14(23):2337–2347

129. Tozzi A, de Iure A, Di Filippo M, Tantucci M, Costa C, Borsini F et al (2011) The distinct role of medium spiny neurons and cholinergic interneurons in the D(2)/A(2A) receptor interaction in the striatum: Implications for Parkinson’s disease. J Neurosci Off J Soc Neurosci 31(5):1850–1862

130. Farkas S, Nagy K, Jia Z, Hankany T, Palkovits M, Donohou SH et al (2012) The decrease of dopamine D(2)/D(3) receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB(1) cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D(2)/D(3) antagonist [(3)H]raclopride and the novel CB(1) inverse agonist [(1)(2)(5)] iodinated Salvinorin A. Brain Res Bull 87(6):504–510

131. Bisogno T, Di Marzo V (2010) Cannabinoid receptors and endocannabinoids: roles in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets 9(5):564–573

132. Pisani V, Madeo G, Tassone A, Sciamanna G, Maccarrone M, Stanzione P et al (2011) Homeostatic changes of the endocannabinoid system in Parkinson’s disease. Mov Disord 26(2):216–222

133. Nisbet AP, Foster OJ, Kingsbury A, Eve DJ, Daniel SE, Marsden CD et al (1995) Preproenkephalin and preprotyrpkhin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience 66(2):361–376

134. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2002) Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61(2):186–196

135. Hanrieder J, Ljungdahl A, Falth M, Mammo SE, Bergquist J, Andersson M (2011) L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry. Mol Cell Proteomics 10(10):M111.009308

136. Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA et al (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci Off J Soc Neurosci 27(26):6995–7005

137. Huot P, Johnston TH, Korchib JB, Fox SH, Brotchie JM (2013) The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev 65(1):171–222

138. Wang Y, Zhang QJ, Wang HS, Wang T, Liu J (2014) Genome-wide microarray analysis identifies a potential role for striatal retrograde endocannabinoid signaling in the pathogenesis of experimental L-DOPA-induced dyskinesia. Synapse 68(8):332–343

139. Berrendero F, Mendizabal V, Robledo P, Galeote L, Bilkei-Gorzo A, Zimmer A et al (2005) Nicotine-induced antinoicception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J Neurosci Off J Soc Neurosci 25(5):1103–1112

140. Meyer-Lindenberg A, Straub RE, Lipska BK, Verchinski BA, Goldberg T, Callicott JH et al (2007) Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 117(3):672–682

141. Kolsch H, Wagner M, Bilkei-Gorzo A, Toliat MR, Pentzek M, Fuchs A et al (2009) Gene polymorphisms in prodynorphin
(PDYN) are associated with episodic memory in the elderly. J Neural Transm 116(7):897–903
142. Frank MJ, Fossella JA (2011) Neurogenetics and pharmacology of learning, motivation, and cognition. Neuropsychopharmacology 36(1):133–152
143. Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S (2011) Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci 5:57
144. Votinov M, Pripil J, Windischberger C, Moser E, Sailer U, Lamm C (2015) A functional polymorphism in the prodynorphin gene affects cognitive flexibility and brain activation during reversal learning. Front Behav Neurosci 9:172
145. Voorn P, Vanderschuren LJ, Groenewegen HJ, Robbins TW, Pennartz CM (2004) Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci 27(8):468–474
146. Haber SN (2016) Corticostriatal circuitry. Dialogues Clin Neurosci 18(1):7–21